Business Daily Media

Business Marketing

.

Eisai Submits Marketing Authorization Application in Japan for Anticancer Agent Denileukin Diftitox (Genetic Recombinant)

  • Written by ACN Newswire - Press Releases

image

TOKYO, Mar 26, 2020 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has submitted in Japan a marketing authorization application of the anticancer agent denileukin diftitox (genetic recombinant) (generic name, development code: E7777) for relapsed or refractory Cutaneous T-cell Lymphoma (CTCL) and Peripheral T-cell Lymphoma (PTCL).

Thi

Read more //?#

Popular

5 Consulting Services That Will Optimize Your Business

Consultation refers to the act of seeking professional advice to make informed decisions. It helps businesses identify areas of improvement and potential growth. There are many different types of consulting services available to...

The CEO Magazine's Executive of the Year Awards

What do you get when you take the Managing Director of Twitter, the CEO of Sportsgirl, the Founder of OzHarvest, the COO of Maserati ANZ and 11 other successful Australian executives and put them in a room together? This year’s ...

New research reveals employee pay gaps exist across 2 in 3 organisations

An industry association has released new data that shows that large-scale pay rate discrepancies occur in 2 in 3 organisations.   The findings come from a survey commissioned by the Australian Payroll Association (Australian ...